Neuropathy and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To describe the development and progression of neuropathy and related findings among patients with type 1 diabetes who participated in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. RESEARCH DESIGN AND METHODS: The main diabetic peripheral neuropathy (DPN) outcome was assessed using clinical symptoms, signs, and nerve conduction study results during DCCT and repeated in EDIC year 13/14. Cardiovascular autonomic neuropathy (CAN) was assessed by R-R response to paced breathing, Valsalva ratio, and blood pressure response to standing during DCCT and in EDIC years 13/14 and 16/17. Additionally, symptoms reflecting neuropathic pain and autonomic function (including hypoglycemia awareness) were collected yearly in EDIC using standardized questionnaires; peripheral neuropathy was also assessed annually using the Michigan Neuropathy Screening Instrument. Assessments of genitourinary function were collected at EDIC year 10. RESULTS: Intensive therapy during the DCCT significantly reduced the risk of DPN and CAN at DCCT closeout (64% and 45%, respectively, P < 0.01). The prevalence and incidence of DPN and CAN remained significantly lower in the DCCT intensive therapy group compared with the DCCT conventional therapy group through EDIC year 13/14. CONCLUSIONS: The persistent effects of prior intensive therapy on neuropathy measures through 14 years of EDIC largely mirror those observed for other diabetes complications. DCCT/EDIC provides important information on the influence of glycemic control, and the clinical course of diabetic neuropathy, and, most important, on how to prevent neuropathy in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A combination of typical symptomatology and symmetrical distal sensory loss, or typical signs in the absence of symptoms, in a person with DM is highly suggestive of DPN and may not require additional evaluations or referral.547,565–567”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The diagnosis of DPN is principally a clinical one.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Diabetes Control and Complications Trial (DCCT) and its observational follow-up study, Epidemiology of Diabetes Interventions and Complications (EDIC), conclusively demonstrated that intensive glucose control applied early in the course of type 1 diabetes (T1D), significantly reduces the risk of developing CAN [2–4].”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Electrophysiological testing or referral to a neurologist is rarely needed for diagnosis, except in situations where the clinical features are atypical, the diagnosis is unclear, and a different etiology is suspected.547,554,565”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
The global burden of diabetic foot disease
Boulton, A. J., Vileikyte, L., Ragnarson-Tennvall, G., & Apelqvist, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67698-2 · Cited by 2,566 · cited 1×
“Painful symptoms are frequently refractory to treatment, and loss of protective sensation heightens the risk for foot ulceration and lowerextremity amputations (19,20).”
BackgroundVascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Spallone, V., Ziegler, D., Freeman, R., Bernardi, L., Frontoni, S., Pop‐Busui, R., Stevens, M., Kempler, P., Hilsted, J., Tesfaye, S., et al. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1239 · Cited by 957
Self-citationEffect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maser, R. E., Mitchell, B. D., Vinik, A. I., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1895 · Cited by 578 · cited 1×
“Yet, CAN is an independent predictor of mortality (21,22), possibly by promoting life-threatening arrhythmias and sudden death in response to a variety of insults including drug side effects, hypoglycemia, hypokalemia, hypotension, or ischemia (23).”
Background
Cited by
Diabetic neuropathy: A position statement by the American Diabetes Association
Pop-Busui, R., Boulton, A. J. M., Feldman, E. L., Bril, V., Freeman, R., Malik, R. A., Sosenko, J. M., & Ziegler, D. (2017) · Diabetes Care · doi:10.2337/dc16-2042 · Cited by 2,602
“The highly reproducible and sensitive testing protocol, the robust definitions used for CAN, and the large sample size in DCCT/EDIC enhance the validity of the results and support the rationale for implementing and maintaining tight glucose control as early as possible in the course of type 1 diabetes.”
BackgroundMethodInfluentialSelf-citationNathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Feldman, E. L., Callaghan, B. C., Pop-Busui, R., Zochodne, D. W., Wright, D. E., Bennett, D. L., Bril, V., Russell, J. W., & Viswanathan, V. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0092-1 · Cited by 1,697
Self-citationNew Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain
Feldman, E. L., Nave, K.-A., Jensen, T. S., & Bennett, D. L. H. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.005 · Cited by 915
Differentiation of diabetes by pathophysiology, natural history, and prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., et al. (2017) · Diabetes · doi:10.2337/db16-0806 · Cited by 823
Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes
Hicks, C. W., & Selvin, E. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1212-8 · Cited by 798
The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) · Diabetes Care · doi:10.2337/dc15-1990 · Cited by 712
Chamberlain, J. J., Rhinehart, A. S., Shaefer, C. F., & Neuman, A. (2016) · Annals of Internal Medicine · doi:10.7326/m15-3016 · Cited by 631
Schalkwijk, C. G., & Stehouwer, C. D. A. (2020) · Physiological Reviews · doi:10.1152/physrev.00001.2019 · Cited by 622
Selvarajah, D., Kar, D., Khunti, K., Davies, M. J., Scott, A. R., Walker, J., & Tesfaye, S. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30081-6 · Cited by 556
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationDiabetic Peripheral Neuropathy: Epidemiology, Diagnosis, and Pharmacotherapy
Iqbal, Z., Azmi, S., Yadav, R., Ferdousi, M., Kumar, M., Cuthbertson, D. J., Lim, J., Malik, R. A., & Alam, U. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.04.001 · Cited by 487
“5 years of follow-up.(8) By the 5th year of the EDIC study, despite HbA1c values in the 2 groups being similar (8.”
BackgroundInfluential11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease
Horton, W. B., & Barrett, E. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa025 · Cited by 424
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
Doria, A., Galecki, A. T., Spino, C., Pop-Busui, R., Cherney, D. Z., Lingvay, I., Parsa, A., Rossing, P., Sigal, R. J., Afkarian, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916624 · Cited by 377
Self-citationDiabetic Neuropathy: Mechanisms, Emerging Treatments, and Subtypes
Albers, J. W., & Pop-Busui, R. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0473-5 · Cited by 357
Self-citationFishman, S. L., Sonmez, H., Basman, C., Singh, V., & Poretsky, L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0060-3 · Cited by 330
Diabetic nephropathy—emerging epigenetic mechanisms
Kato, M., & Natarajan, R. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.116 · Cited by 318
Glucose Control and Diabetic Neuropathy: Lessons from Recent Large Clinical Trials
Ang, L., Jaiswal, M., Martin, C., & Pop-Busui, R. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0528-7 · Cited by 303
Self-citation10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s010 · Cited by 302
Spallone, V. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0259 · Cited by 295
“Glycaemic control and CAN There is clear evidence for the efficacy of intensive treatment of hyperglycaemia in T1DM with a prolonged benefit (EDIC study) [28], whereas efficacy is only apparent in the setting of a multifactorial strategy in T2DM and with prolonged benefits [129], albeit not confirmed in the ADDITION s…”
Background(2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0097-9 · Cited by 254
Self-citationBharucha, A. E., Kudva, Y. C., & Prichard, D. O. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00161 · Cited by 252
Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment
Serhiyenko, V. A., & Serhiyenko, A. A. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i1.1 · Cited by 251
INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES
Baru, P. C. R. (2014) · ADVANCED SCIENCES INDEX · Cited by 236
Diabetic neuropathy: cutting-edge research and future directions
Yang, Y., Zhao, B., Wang, Y., Lan, H., Liu, X., Hu, Y., & Cao, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02175-1 · Cited by 234
“340 Understanding the role of insulin signaling and insulin resistance in peripheral nerves is essential for developing targeted therapies for DPN. Recent therapeutic approaches focus on enhancing insulin signaling pathways or reducing insulin resistance within peripheral nerves to improve…”
Anti-diabetic drugs recent approaches and advancements
Dowarah, J., & Singh, V. P. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115263 · Cited by 227
Braffett, B. H., Gubitosi-Klug, R. A., Albers, J. W., Feldman, E. L., Martin, C. L., White, N. H., Orchard, T. J., Lopes-Virella, M., Lachin, J. M., Pop-Busui, R., et al. (2020) · Diabetes · doi:10.2337/db19-1046 · Cited by 221
Self-citation12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s012 · Cited by 207
Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015
Papanas, N., & Ziegler, D. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.48 · Cited by 207
“The beneficial effect of this strategy is undeniable in T1D [19, 20, 29, 156], but has hitherto not proved significant in T2D [33-35].”
BackgroundInfluential12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Callaghan, B. C., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s012 · Cited by 204
Zhu, X., Wu, C., Qiu, S., Yuan, X., & Li, L. (2017) · Nutrition & Metabolism · doi:10.1186/s12986-017-0217-z · Cited by 196
“These complications pose a major threat to general public health worldwide and lead to high economic costs [3, 4].”
BackgroundZiegler, D., Tesfaye, S., Spallone, V., Gurieva, I., Al Kaabi, J., Mankovsky, B., Martinka, E., Radulian, G., Nguyen, K. T., Stirban, A. O., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109063 · Cited by 196
Health-related quality of life among adults living with diabetic foot ulcers: a meta-analysis
Khunkaew, S., Fernandez, R., & Sim, J. (2019) · Quality of Life Research · doi:10.1007/s11136-018-2082-2 · Cited by 196
The global and regional burden of diabetic peripheral neuropathy
Savelieff, M. G., Elafros, M. A., Viswanathan, V., Jensen, T. S., Bennett, D., & Feldman, E. L. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01041-y · Cited by 194
“These recommendations are based on large studies of people with T1D, such as the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study, which showed that optimized glucose control is effective for suppressing DPN development in these individuals 95 .”
Diabetic Nephropathy: a Tangled Web to Unweave
Magee, C., Grieve, D. J., Watson, C. J., & Brazil, D. P. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6755-9 · Cited by 190
Autonomic Neuropathy in Diabetes Mellitus
Verrotti, A., Prezioso, G., Scattoni, R., & Chiarelli, F. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00205 · Cited by 187
Understanding Diabetic Neuropathy: Focus on Oxidative Stress
Pang, L., Lian, X., Liu, H., Zhang, Y., Li, Q., Cai, Y., Ma, H., & Yu, X. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9524635 · Cited by 184
10. Microvascular Complications and Foot Care
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s013 · Cited by 181
12. Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s012 · Cited by 177
Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events
Vinik, A. I., CASELLINI, C. M., Parson, H. K., Colberg, S. R., & Névoret, M.-L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00591 · Cited by 177
“Moreover, weight reduction significantly improves HRV and reduces ANS imbalances (Karason et al., 1999; Maser et al., 2007; Nault et al., 2007; Perugini et al., 2010; Ravussin, 2010; Casellini et al., 2015, 2016; Ziegler et al., 2015a).”
Background12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Callaghan, B. C., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s012 · Cited by 176
Advances in Screening, Early Diagnosis and Accurate Staging of Diabetic Neuropathy
Carmichael, J., Fadavi, H., Ishibashi, F., Shore, A. C., & Tavakoli, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.671257 · Cited by 176
“The Epidemiology of Diabetes Interventions and Complications (EDIC) trial reported that intensive glucose control signi fi cantly delayed the development and progression of diabetic neuropathy in T1DM patients over time (17).”
BackgroundAdvanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes
Yamagishi, S.-I., Nakamura, N., Suematsu, M., Kaseda, K., & Matsui, T. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00067 · Cited by 173
Current concepts in the management of diabetic polyneuropathy
Ziegler, D., Παπάνας, Ν., Schnell, O., Nguyen, B. D., Nguyen, K. T., Kulkantrakorn, K., & Deerochanawong, C. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13401 · Cited by 171
9. Microvascular Complications and Foot Care
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s012 · Cited by 171
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s012 · Cited by 169
Lachin, J. M., & Nathan, D. M. (2021) · Diabetes Care · doi:10.2337/dc20-3097 · Cited by 163
Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study
Gubitosi‐Klug, R., Braffett, B. H., White, N. H., Sherwin, R. S., Service, F. J., Lachin, J. M., & Tamborlane, W. V. (2017) · Diabetes Care · doi:10.2337/dc16-2723 · Cited by 160
Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms?
Calcutt, N. A. (2020) · Pain · doi:10.1097/j.pain.0000000000001922 · Cited by 159
“This was encouraged by results from the Diabetic Control and Complications Trial (DCCT) study, which showed that improved glycemic control beyond the accepted standard of care slowed the onset and progression of diabetic complications, including peripheral neuropathy, in a large cohort of type 1 diabetic patients.(226…”
BackgroundResultBharucha, A. E., Batey-Schaefer, B., Cleary, P. A., Murray, J. A., Cowie, C., Lorenzi, G., Driscoll, M., Harth, J., Larkin, M., Christofi, M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.007 · Cited by 156
Self-citationUric Acid as a Biomarker and a Therapeutic Target in Diabetes
Lytvyn, Y., Perkins, B. A., & Cherney, D. Z. I. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.10.013 · Cited by 152
Gubitosi‐Klug, R. (2013) · Diabetes Care · doi:10.2337/dc13-2148 · Cited by 146
Insulin pump therapy in children with type 1 diabetes: analysis of data from the SWEET registry
Szypowska, A., Schwandt, A., Svensson, J., Shalitin, S., Cardona‐Hernandez, R., Forsander, G., Sundberg, F., de Beaufort, C. E., Maahs, D. M., Maffeis, C., et al. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12416 · Cited by 140
9. Microvascular Complications and Foot Care
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc15-s012 · Cited by 137
Yamagishi, S., Fukami, K., & Matsui, T. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0176-5 · Cited by 135
“Recently, intensive diabetes treatment has been shown to yield durable retinal and renal benefits that persist for at least 18 years after its application [13,14], and the prevalence and incidence of diabetic peripheral neuropathy and cardiovascular autonomic neuropathy have remained significantly lower in the DCCT in…”
ResultDiabetic peripheral neuropathy essentials: a narrative review
Chang, M. C., & Yang, S. (2023) · Annals of Palliative Medicine · doi:10.21037/apm-22-693 · Cited by 134
Chowdhury, M., Nevitt, S. J., Eleftheriadou, A., Kanagala, P., Esa, H., Cuthbertson, D. J., Tahrani, A. A., & Alam, U. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002480 · Cited by 125
Pop-Busui, R., Braffett, B. H., Zinman, B., Martin, C., White, N. H., Herman, W. H., Genuth, S., Gubitosi-Klug, R., & the DCCT/EDIC Research Group (2017) · Diabetes Care · doi:10.2337/dc16-1397 · Cited by 116
“Patients with event 183 (13) 167 (12) 15 (27) 167 (13) 13 (16) 165 (12) 18 (27)”
Self-citationManagement of diabetic neuropathy
Cernea, S., & Raz, I. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154867 · Cited by 115
Role of the Gastrointestinal Tract Microbiome in the Pathophysiology of Diabetes Mellitus
Sohail, M. U., Thani, A. A. A., Anwar, H., Rizzi, R., & Marei, H. E. S. (2017) · Journal of Diabetes Research · doi:10.1155/2017/9631435 · Cited by 113
“Over time, diabetes can lead to secondary complications, such as cardiovascular disease, cerebrovascular disease, neuropathy, retinopathy, nephropathy, and limb amputation [10, 11].”
BackgroundCardiac Autonomic Neuropathy in Type 1 and 2 Diabetes: Epidemiology, Pathophysiology, and Management
Williams, S., Raheim, S. A., Khan, M. I., Rubab, U., Kanagala, P., Zhao, S. S., Worthington, A., Brown, E. E., & Alam, U. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.09.002 · Cited by 112
2021 Guidelines on the management of patients with diabetes. A position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2021) · Clinical Diabetology · doi:10.5603/dk.2021.0001 · Cited by 110
The Inferior Whorl For Detecting Diabetic Peripheral Neuropathy Using Corneal Confocal Microscopy
Petropoulos, I. N., Ferdousi, M., Marshall, A. G., Alam, U., Ponirakis, G., Azmi, S., Fadavi, H., Efron, N., Tavakoli, M., & Malik, R. A. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15919 · Cited by 107
The effects of capillary dysfunction on oxygen and glucose extraction in diabetic neuropathy
Østergaard, L., Finnerup, N. B., Terkelsen, A. J., Olesen, R. A., Drasbek, K. R., Knudsen, L., Jespersen, S. N., Frystyk, J., Charles, M., Thomsen, R. W., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3461-z · Cited by 104
“Early, intensive glycaemic control indeed delays the onset of type 1 diabetes complications, including diabetic neuropathy [84].”
BackgroundSpectrum of Diabetic Neuropathy: New Insights in Diagnosis and Treatment
Dillon, B. R., Ang, L. P., & Pop‐Busui, R. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-033114 · Cited by 103
Self-citationTreating Diabetic Neuropathy: Present Strategies and Emerging Solutions
Javed, S., Alam, U., & Malik, R. A. (2015) · The Review of Diabetic Studies · doi:10.1900/rds.2015.12.63 · Cited by 101
“The Epidemiology of Diabetes Interventions and Complications (EDIC) was an observational study that followed up 90% of the DCCT cohort to determine the long-term impact of prior improvement in glycemic control on micro- and macrovascular outcomes [42, 43].”
MethodJaiswal, M., Martin, C. L., Brown, M. B., Callaghan, B. C., Albers, J. W., Feldman, E. L., & Pop‐Busui, R. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.013 · Cited by 100
“Intensive glycemic control is essential but insufficient to completely prevent onset or progression of diabetic neuropathy (5,30).”
BackgroundSelf-citationBril, V., Breiner, A., Perkins, B. A., & Zochodne, D. W. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.028 · Cited by 98
Prevention and Management Strategies for Diabetic Neuropathy
Smith, S., Normahani, P., Lane, T. R. A., Hohenschurz‐Schmidt, D., Oliver, N. S., & Davies, A. H. (2022) · Life · doi:10.3390/life12081185 · Cited by 98
“The cases of DN had increased significantly from 6% at baseline to 30% at final follow-up, implicating age, duration of diabetes and chronic hyperglycemia as risk factors [36,37].”
BackgroundResultMizokami‐Stout, K., Li, Z., Foster, N. C., Shah, V. N., Aleppo, G., McGill, J. B., Pratley, R. E., Toschi, E., Ang, L. P., Pop‐Busui, R., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1583 · Cited by 96
“EURODIAB, found prevalence rates up to 34% after an average of 25 years of diabetes duration (1,8,9,16,17).”
BackgroundSelf-citationEpidemiology and Natural History of Gastroparesis
Bharucha, A. E. (2014) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2014.11.002 · Cited by 92
Ziegler, D., Low, P. A., Freeman, R. L., Tritschler, H., & Vinik, A. I. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.10.018 · Cited by 89
Yovera-Aldana, M., Velásquez‐Rimachi, V., Huerta‐Rosario, A., More-Yupanqui, M. D., Osores-Flores, M., Espinoza, R., Gil-Olivares, F., Quispe-Nolazco, C. M., Quea-Vélez, F., Morán‐Mariños, C., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251642 · Cited by 85
Current Pharmacological Treatment of Painful Diabetic Neuropathy: A Narrative Review
Ardeleanu, V., Alexandra Monica, T. O. M. A., Pafili, K., Παπάνας, Ν., Motofei, I. G., Diaconu, C. C., Rizzo, M., & Stoian, A. P. (2020) · Medicina · doi:10.3390/medicina56010025 · Cited by 85
2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 84
Perveen, W., Ahsan, H., Shahzad, R., Fayyaz, S., Zaif, A., Paracha, M. A., Nuhmani, S., Khan, M., & Alghadir, A. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-65495-2 · Cited by 84
Lin, Y. K., Fisher, S. J., & Pop‐Busui, R. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13290 · Cited by 82
Self-citationCorneal confocal microscopy for the diagnosis of diabetic autonomic neuropathy
Tavakoli, M., Begum, P., McLaughlin, J. T., & Malik, R. A. (2014) · Muscle & Nerve · doi:10.1002/mus.24553 · Cited by 81
Diabetic Peripheral Neuropathy: Diagnosis and Treatment
Røikjer, J., Mørch, C. D., & Ejskjær, N. (2020) · Current Drug Safety · doi:10.2174/1574886315666200731173113 · Cited by 79
“The DCCT/EDICstudy was one of the hallmark studies indicating a beneficial effect of intensified glycaemic control even years after terminating the intervention [86].”
Burning through the pain: treatments for diabetic neuropathy
Javed, S., Alam, U., & Malik, R. A. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12535 · Cited by 78
“Remarkably, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, which followed up 90% of the patients from the DCCT, found that the reduced prevalence of DPN persisted in the intensive control group 14 years after the DCCT ended, despite broadly similar levels of glycaemic control during EDIC [2…”
BackgroundZiegler, D., Behler, M., Schroers-Teuber, M., & Roden, M. (2015) · BMJ Open · doi:10.1136/bmjopen-2014-006559 · Cited by 74
“robust predictor of DSPN and CAN in patients with type 1 diabetes.(5) The persistent long-term favourable effects shown during EDIC of the prior intensive insulin therapy (IT) compared with conventional insulin therapy (CT) during”
BackgroundInfluentialCheng, C., Kobayashi, M., Martinez, J. A., Ng, H., Moser, J. J., Wang, X., Singh, V., Fritzler, M. J., & Zochodne, D. W. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000219 · Cited by 73
Vaisar, T., Kanter, J. E., Wimberger, J., Irwin, A. D., Gauthier, J., Wolfson, E. A., Bahnam, V., Wu, I., Shah, H., Keenan, H. A., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0772 · Cited by 73
Impaired wound healing in diabetes
Swoboda, L., & Held, J. (2022) · Journal of Wound Care · doi:10.12968/jowc.2022.31.10.882 · Cited by 72
The Treatment of Painful Diabetic Neuropathy
SLOAN, G. P., Alam, U., Selvarajah, D., & Tesfaye, S. H. (2021) · Current Diabetes Reviews · doi:10.2174/1573399817666210707112413 · Cited by 71
He, R., Hu, Y., Zeng, H., Zhao, J., Zhao, J., Chai, Y., Lu, F., Liu, F., & Jia, W. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2820 · Cited by 71
“polyneuropathy) and abnormal results on nerve conduction tests (defined as the presence of at least one abnormal nerve attribute (of amplitude, latency, F-wave or nerve conduction velocity (NCV)) in two or more nerves among the median, peroneal and sural nerves), (ii) signs of DPN, patients had either clinical evident…”
BackgroundMathew, A. V., Jaiswal, M., Ang, L. P., Michailidis, G. C., Pennathur, S., & Pop‐Busui, R. (2019) · Diabetes · doi:10.2337/db19-0145 · Cited by 71
Self-citationDiagnóstico e tratamento da neuropatia periférica diabética
Rolim, L. C., Thyssen, P. J., Flumignan, R. L., de Andrade, D. C., Dib, S. A., & Bertoluci, M. C. (2022) · Conectando Pessoas eBooks · doi:10.29327/557753.2022-14 · Cited by 70
Functional and proteomic alterations of plasma high density lipoproteins in type 1 diabetes mellitus
Manjunatha, S., Distelmaier, K., Dasari, S., Carter, R. E., Kudva, Y. C., & Nair, K. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.06.008 · Cited by 67
Effect of Acupuncture on Diabetic Neuropathy: A Narrative Review
Cho, E., & Kim, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168575 · Cited by 65
“However, large meta-analyses have reported that glycemic control has minimal effect on neuropathy patients, especially in patients with type 2 diabetes [5], suggesting that focusing only on glycemic control may not be sufficient to attenuate diabetic neuropathy.”
BackgroundContinuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment.
(2018) · Europe PMC (PubMed Central) · Cited by 64
Differences and Similarities in Neuropathy in Type 1 and 2 Diabetes: A Systematic Review
Sempere‐Bigorra, M., Julían-Rochina, I., & Cauli, O. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030230 · Cited by 62
“The prevalence of diabetic peripheral neuropathy in adults with type 1 diabetes is 6% at the onset of the disease, increasing to 30% after 13–14 years of progression [11,12].”
BackgroundThe Role of Biofactors in Diabetic Microvascular Complications
Ziegler, D., Porta, M., Παπάνας, Ν., Moța, M., Jermendy, G., Beltramo, E., Mazzeo, A., Caccioppo, A., Striglia, E., Serhiyenko, V. A., et al. (2021) · Current Diabetes Reviews · doi:10.2174/1871527320666210825112240 · Cited by 61
Peytam, F., Adib, M., Shourgeshty, R., Firoozpour, L., Rahmanian-Jazi, M., Jahani, M., Moghimi, S., Divsalar, K., Faramarzi, M. A., Mojtabavi, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59079-z · Cited by 59
Riddell, M. C., Li, Z., Beck, R. W., Gal, R. L., Jacobs, P. G., Castle, J. R., Gillingham, M. B., Clements, M. A., Patton, S. R., Dassau, E., et al. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0495 · Cited by 59
Self-citationFranceschi, R., Mozzillo, E., Candia, F. D., Rosanio, F. M., Leonardi, L., Liguori, A., Micheli, F., Cauvin, V., Franzese, A., Piona, C. A., et al. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01850-x · Cited by 58
Persistent Insulin Resistance in Podocytes Caused by Epigenetic Changes of SHP-1 in Diabetes
Lizotte, F., Denhez, B., Guay, A., Gévry, N. Y., Côté, A. M., & Geraldes, P. (2016) · Diabetes · doi:10.2337/db16-0254 · Cited by 58
Metadata
- Authors
- Martin, C. L., Albers, J. W., Pop-Busui, R., & for the DCCT/EDIC Research Group
- Affiliations
- University of Michigan (US)
- Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School, Ann Arbor, MI
- Corresponding author
- Martin, Catherine L.
- ORCID
- Martin, Catherine L.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-12-11
- Volume
- 37
- Issue
- 1
- Pages
- 31-38
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3868000
- OpenAlex
- W2115038969
- Cited by
- 499
- References
- 30
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 45 · 2023: 38 · 2022: 40 · 2021: 57 · 2020: 50 · 2019: 41 · 2018: 45 · 2017: 28 · 2016: 34 · 2015: 42 · 2014: 23 · 2013: 4
- FWCI
- 27.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Sanofi
- BD
- Roche Diabetes Care
- National Institutes of Health (UL1TR000041, UL1TR000114, 5u01dk094157-13, UL1TR001449)
- Abbott Diabetes Care
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK094176, U01-DK094157, P30DK020572)
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- diabetic peripheral neuropathy, cardiac autonomic neuropathy, type 1 diabetes, tight glycemic control, neuropathy progression, neuropathic pain, hypoglycemia awareness, genitourinary function, Michigan Neuropathy Screening Instrument, DCCT/EDIC, neuropathy prevention
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 1, Diabetic Neuropathies, Dose-Response Relationship, Drug, Female, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Neural Conduction, Peripheral Nervous System Diseases, Risk Factors, Incidence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.